<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="66399"><DrugName>DMXD-011</DrugName><DrugSynonyms><Name><Value>IKK-epsilon/TBK 1 inhibitors (breast cancer), Domainex/Breakthrough Breast Cancer/Institute of Cancer Research</Value></Name><Name><Value>IKK-epsilon/TBK 1 inhibitors (breast/ovarian cancer/inflammatory disease), Domainex/Breakthrough Breast Cancer</Value></Name><Name><Value>DMXD-011</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IKK-epsilon/TBK 1 inhibitors (breast/ovarian cancer/inflammatory disease/ obesity), Domainex/Breakthrough Breast Cancer</Value></Name><Name><Value>WEHI‐112</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1018324">Breakthrough Breast Cancer</CompanyOriginator><CompaniesPrimary><Company id="1049525">Domainex Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="1018324">Breakthrough Breast Cancer</Company><Company id="21072">Institute of Cancer Research UK</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1018324" type="Company"><TargetEntity id="5003630344" type="organizationId">Breakthrough Breast Cancer</TargetEntity></SourceEntity><SourceEntity id="1049525" type="Company"><TargetEntity id="4297879813" type="organizationId">Domainex Ltd</TargetEntity></SourceEntity><SourceEntity id="21072" type="Company"><TargetEntity id="4297014876" type="organizationId">Institute of Cancer Research: Royal Cancer Hospital</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="18583" type="Action"><TargetEntity id="3756" type="Mechanism">IKBKE (IKK-epsilon; IKK-i) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="68995" type="Action"><TargetEntity id="3754" type="Mechanism">TANK-Binding Kinase 1 (TBK1; NAK; T2K) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-04404" type="ciTarget"><TargetEntity id="209554577496413" type="siTarget">Inhibitor of nuclear factor kappa-B kinase subunit epsilon</TargetEntity><TargetEntity id="2154" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-12071" type="ciTarget"><TargetEntity id="7357046291103" type="siTarget">Serine/threonine-protein kinase TBK1</TargetEntity><TargetEntity id="4022" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="188">Inflammatory disease</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="49">Breast tumor</Indication><Indication id="799">Ovary tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="68995">Serine threonine protein kinase TBK1 inhibitor</Action><Action id="18583">I-kappa B kinase epsilon inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-05-28T11:56:15.000Z</LastModificationDate><ChangeDateLast>2019-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>2010-05-10T12:50:29.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1049525" linkType="Company"&gt;Domainex&lt;/ulink&gt;  is investigating DMXD-011, a lead from TANK-binding kinase 1 (TBK1) and, IkappaB kinase epsilon (IKKepsilon) inhibitors and also inhibits salt-inducible kinase 2 (SIK2), using the company's Leadbuilder technology, for the potential oral treatment of    inflammatory diseases such as COPD,  systemic lupus erythematosus (lupus, SLE), rheumatoid arthritis (RA)  and inflammatory bowel disease [&lt;ulink linkID="1040139" linkType="Reference"&gt;1040139&lt;/ulink&gt;], [&lt;ulink linkID="1096739" linkType="Reference"&gt;1096739&lt;/ulink&gt;], [&lt;ulink linkID="1096741" linkType="Reference"&gt;1096741&lt;/ulink&gt;], [&lt;ulink linkID="1235178" linkType="Reference"&gt;1235178&lt;/ulink&gt;],  [&lt;ulink linkID="1543510" linkType="Reference"&gt;1543510&lt;/ulink&gt;], [&lt;ulink linkID="1894023" linkType="Reference"&gt;1894023&lt;/ulink&gt;]. In November 2012, preclinical data were reported and at that time, the company was planning to develop the program for psoriasis, COPD and lupus [&lt;ulink linkID="1337435" linkType="Reference"&gt;1337435&lt;/ulink&gt;]; in April 2014, preclinical data were reported from inflammatory models  and at that time, further in vivo studies were planned in models of inflammatory diseases including COPD   [&lt;ulink linkID="1543510" linkType="Reference"&gt;1543510&lt;/ulink&gt;]; in July 2014, preclinical data of the lead compound were reported [&lt;ulink linkID="1575861" linkType="Reference"&gt;1575861&lt;/ulink&gt;]. In January 2017,  the program was listed as being in lead optimization; at that time, the company was seeking to outlicense the program [&lt;ulink linkID="1894023" linkType="Reference"&gt;1894023&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Domainex, in collaboration with &lt;ulink linkID="1018324" linkType="Company"&gt;Breakthrough Breast Cancer&lt;/ulink&gt; Research Center and  &lt;ulink linkID="21072" linkType="Company"&gt;The Institute of Cancer Research&lt;/ulink&gt;,  was previously investigating the inhibitor program for the potential treatment of    breast  cancer [&lt;ulink linkID="1040139" linkType="Reference"&gt;1040139&lt;/ulink&gt;], [&lt;ulink linkID="1096739" linkType="Reference"&gt;1096739&lt;/ulink&gt;], [&lt;ulink linkID="1096741" linkType="Reference"&gt;1096741&lt;/ulink&gt;]. Domainex was also investigating the inhibitors for the potential  oral treatment of ovarian cancer, obesity and inflammatory diseases such as COPD,  systemic lupus erythematosus (lupus, SLE) and rheumatoid arthritis (RA)  [&lt;ulink linkID="1235178" linkType="Reference"&gt;1235178&lt;/ulink&gt;]. However, no further development was reported for those indications. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In January 2017, the company was planning for a clinical proof-of-concept study [&lt;ulink linkID="1894023" linkType="Reference"&gt;1894023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, the company was planning for phase I trials [&lt;ulink linkID="1575861" linkType="Reference"&gt;1575861&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In July 2018, preclinical data were published. The drug showed significant reduction in arthritogenic collagen-specific IgG1 and IgG2b antibodies and reduced the size of established germinal centres (GC) through inhibition of Fox01 phosphorylation in TFH cells [&lt;ulink linkID="2106544" linkType="Reference"&gt;2106544&lt;/ulink&gt;]. In December 2018, similar data were reported [&lt;ulink linkID="2106519" linkType="Reference"&gt;2106519&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;n January 2017, DMXD-011 exhibited high potency in in vivo models of disease, was orally bioavailable and had excellent drug-like properties [&lt;ulink linkID="1894023" linkType="Reference"&gt;1894023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, the candidate nomination was expected in 2014 [&lt;ulink linkID="1584521" linkType="Reference"&gt;1584521&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2014, preclinical data were reported. In a COPD model, the lead compound of the program demonstrated more than twice the effect of the comparator drugs, &lt;ulink linkID="21820" linkType="Drug"&gt;roflumilast&lt;/ulink&gt; and a p38 inhibitor, in reducing the cigarette smoke-induced influx of inflammatory cells into the lung [&lt;ulink linkID="1575861" linkType="Reference"&gt;1575861&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, preclinical data were reported. In a series of four separate studies in inflammatory models, the compounds  were found to inhibit the expression of a number of pro-inflammatory cytokines including TNF-alpha, RANTES, IL-1-beta, and IL-6, and also prolonged activity for at least 20 hours was observed against many of the cytokines. At that time, further in vivo studies were planned in models of inflammatory diseases   [&lt;ulink linkID="1543510" linkType="Reference"&gt;1543510&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, preclinical data were reported. The small molecule inhibitors of TBK1/IKKepsilon were found to affect IL-17 signaling and block interferon-beta production in immune cells. At that time, the company was planning to develop the program for psoriasis, COPD and lupus [&lt;ulink linkID="1337435" linkType="Reference"&gt;1337435&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2012, the program was in lead optimization and at that time, candidate drug nomination was expected in early 2012 [&lt;ulink linkID="1278553" linkType="Reference"&gt;1278553&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2011, studies had shown that certain cancer cell line growth was stopped by inhibition of these enzymes [&lt;ulink linkID="1235178" linkType="Reference"&gt;1235178&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2009,     the company planned to initiate studies in a xenograft model in the fourth quarter of 2009 [&lt;ulink linkID="1096739" linkType="Reference"&gt;1096739&lt;/ulink&gt;]. In May 2010, the company planned to initiate studies in a xenograft model in the fourth quarter of 2010 [&lt;ulink linkID="1096741" linkType="Reference"&gt;1096741&lt;/ulink&gt;]. At that time, the program was  in lead optimization   [&lt;ulink linkID="1096741" linkType="Reference"&gt;1096741&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, proof-of-concept studies were planned in   breast cancer models   [&lt;ulink linkID="1040139" linkType="Reference"&gt;1040139&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1049525">Domainex Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2014-04-07T00:00:00.000Z</StatusDate><Source id="1543510" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21072">Institute of Cancer Research UK</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2017-01-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1018324">Breakthrough Breast Cancer</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2017-01-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1049525">Domainex Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2017-01-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1049525">Domainex Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2017-01-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1018324">Breakthrough Breast Cancer</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2009-03-17T00:00:00.000Z</StatusDate><Source id="1040139" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1049525">Domainex Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2009-03-17T00:00:00.000Z</StatusDate><Source id="1040139" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1049525">Domainex Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2011-11-01T00:00:00.000Z</StatusDate><Source id="1235178" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21072">Institute of Cancer Research UK</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2009-03-17T00:00:00.000Z</StatusDate><Source id="1040139" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-04404"><Name>I-kappa B kinase epsilon</Name><SwissprotNumbers><Swissprot>Q14164</Swissprot><Swissprot>Q9R0T8</Swissprot></SwissprotNumbers></Target><Target id="PTGT-12071"><Name>Serine threonine protein kinase TBK1</Name><SwissprotNumbers><Swissprot>Q9UHD2</Swissprot><Swissprot>Q9WUN2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1018022">UK Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1018324">Breakthrough Breast Cancer</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1049525">Domainex Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="21072">Institute of Cancer Research UK</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="127855" title="Domainex and the Institute of Cancer Research to develop inhibitors of breast cancer targets "/><Deal id="130716" title="Domainex and Breakthrough Breast Cancer to identify and develop inhibitors of breast cancer targets"/><Deal id="136800" title="TSB to award Domainex funding for the development of its IKK-epsilon/TBK 1 inhibitors to treat cancer and COPD"/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>